William K. Kelly

3.8k total citations
50 papers, 2.7k citations indexed

About

William K. Kelly is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, William K. Kelly has authored 50 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in William K. Kelly's work include Prostate Cancer Treatment and Research (29 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Bladder and Urothelial Cancer Treatments (8 papers). William K. Kelly is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Bladder and Urothelial Cancer Treatments (8 papers). William K. Kelly collaborates with scholars based in United States, Spain and France. William K. Kelly's co-authors include Howard I. Scher, Tracy Curley, Michael J. Morris, Eric J. Small, John A. McCaffrey, Dean F. Bajorin, Madhu Mazumdar, S Hilton, Karim Fizazi and Susan F. Slovin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

William K. Kelly

46 papers receiving 2.7k citations

Peers

Countries citing papers authored by William K. Kelly

Since Specialization

Citations

This map shows the geographic impact of William K. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William K. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William K. Kelly more than expected).

Fields of papers citing papers by William K. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William K. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William K. Kelly. The network helps show where William K. Kelly may publish in the future.

Co-authorship network of co-authors of William K. Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of William K. Kelly. A scholar is included among the top collaborators of William K. Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William K. Kelly. William K. Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer 2025 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anna Testa, (unknown), William K. Kelly, Susan L. Bellis, Aurelio Lorico, Ada G. Blidner, Gabriel A. Rabinovich, Lucia R. Languino	0
2	Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer 2025 ·Clinical Cancer Research ·Fei Shen, (unknown), (unknown), Krista Menard, Shaozhou K. Tian, Gerald Chu, Ruchi Chaudhary, Jennifer J. McCann, (unknown), Sherry Wang, (unknown), Peter Francis, William K. Kelly, Charles G. Drake	0
3	The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials 2025 ·Cancers ·Amy L. Shaver, (unknown), (unknown), Scott W. Keith, Kevin Zarrabi, William K. Kelly, Grace Lu‐Yao	0
4	Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles 2025 ·Molecular Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ada G. Blidner, Gabriel A. Rabinovich, Alessandro Fatatis, (unknown), David W. Goodrich, Kevin Zarrabi, William K. Kelly, Matthew J. Schiewer, Lucia R. Languino	2
5	Evaluating the Impact of a Novel Program to Address Acute Food Insecurity Among Cancer Patients 2024 ·Nutrients ·(unknown), Michael Rowe, (unknown), (unknown), William K. Kelly, Amy Leader	1
6	1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig 2024 ·Annals of Oncology ·(unknown), (unknown), Daniel C. Danila, C-C. Lin, Jia-Lin Lee, (unknown), Phil Ward, David Pook, (unknown), Tanya B. Dorff, Sabine Fischer, (unknown), Lisa G. Horvath, Christopher Sumey, Zhi Yang, Benjamin E. Decato, (unknown), Katherine Smith, Martijn P. Lolkema, William K. Kelly	1
7	External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer 2023 ·Journal of Clinical Oncology ·Susan Halabi, Qian Yang, (unknown), Bin Luo, John C. Araujo, Christopher J. Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N., Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William K. Kelly	14
8	709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study 2020 ·Annals of Oncology ·Bradley A. McGregor, Neeraj Agarwal, Cristina Suárez, (unknown), William K. Kelly, Lance C. Pagliaro, Ulka N. Vaishampayan, Daniel Castellano, Yohann Loriot, Scott Werneke, Desmond Curran, Toni K. Choueiri, Sumanta K. Pal	10
9	368MO Fatty acid synthase inhibitor TVB-2640 with bevacizumab in recurrent glioblastoma 2020 ·Annals of Oncology ·William K. Kelly, Joel Michalek, (unknown), (unknown), (unknown), (unknown), (unknown), Andrew Brenner	2
10	Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer 2017 ·Annals of Oncology ·Neal D. Shore, Elisabeth I. Heath, Luke T. Nordquist, Heather H. Cheng, (unknown), (unknown), Trevor McMullan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Rahul Atul Parikh, Ronald Tutrone, J. Garcia, Young E. Whang, William K. Kelly, Ildiko Csiki, Mark L. Bagarazzi	1
11	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer 2013 ·Nanomedicine Nanotechnology Biology and Medicine ·Darryl T. Martin, Christopher Hoimes, Hristos Z. Kaimakliotis, Christopher J. Cheng, Ke Zhang, Jingchun Liu, Marcia A. Wheeler, William K. Kelly, (unknown), W. Mark Saltzman, Robert M. Weiss	51
12	Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients 2007 ·Cancer ·Jonathan E. Rosenberg, Vivian Weinberg, William K. Kelly, M. Dror Michaelson, Maha Hussain, George Wilding, Mitchell E. Gross, Douglass Hutcheon, Eric J. Small	138
13	Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration 2003 ·Annals of Oncology ·Òren Smaletz, Matthew D. Galsky, Howard I. Scher, A. Delacruz, Susan F. Slovin, Michael J. Morris, David B. Solit, (unknown), Lawrence H. Schwartz, William K. Kelly	50
14	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract 2000 ·Cancer ·Dean F. Bajorin, John A. McCaffrey, Paul M. Dodd, Susan Hilton, Madhu Mazumdar, William K. Kelly, (unknown), Howard I. Scher, (unknown), Geralyn Higgins	2
15	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract 2000 ·Cancer ·Dean F. Bajorin, John A. McCaffrey, Paul M. Dodd, Susan Hilton, Madhu Mazumdar, William K. Kelly, Harry W. Herr, Howard I. Scher, (unknown), Geralyn Higgins	85
16	Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. 1998 ·Journal of Clinical Oncology ·Dean F. Bajorin, John A. McCaffrey, S Hilton, Madhu Mazumdar, William K. Kelly, Howard I. Scher, James Spicer, H.W. Herr, Geralyn Higgins	70
17	Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. 1997 ·Journal of Clinical Oncology ·John A. McCaffrey, S Hilton, Madhu Mazumdar, (unknown), M.J. Heineman, Joy Hirsch, William K. Kelly, Howard I. Scher, Dean F. Bajorin	40
18	Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. 1995 ·Journal of Clinical Oncology ·William K. Kelly, Tracy Curley, (unknown), Ann M. Dnistrian, Morton K. Schwartz, Howard I. Scher	81
19	Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. 1995 ·Journal of Clinical Oncology ·Ronald Ghossein, Howard I. Scher, William L. Gerald, William K. Kelly, Tracy Curley, Alison Amsterdam, Zuo‐Feng Zhang, Juan Rosaí	183
20	Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatc cancer: A trial with 10-ethyl-deaza-aminopterin 1994 ·Urology ·Paul Schultz, William K. Kelly, Colin B. Begg, (unknown), Lee S. Cohen, Howard I. Scher	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact